Renalytix AI PLC Notice of Results & Change of Auditor (4033B)
June 10 2021 - 1:00AM
UK Regulatory
TIDMRENX
RNS Number : 4033B
Renalytix AI PLC
10 June 2021
Renalytix AI plc
("Renalytix" or the "Company")
Renalytix to Report Financial Results for Fiscal Third Quarter
2021 and Provide Corporate Update
Announces Change of Auditor to Ernst & Young LLP
NEW YORK, June 10, 2021 - Renalytix AI plc (LSE : RENX) (NASDAQ:
RNLX) today announced the Company will release fiscal third quarter
2021 financial results on Tuesday, June 15, 2021, before market
open. The Company will host a corresponding conference call and
live webcast at 8:30 a.m. (EDT) / 1:30 p.m. (BST) to discuss the
results and provide a corporate update.
Conference Call Details:
US/Canada Participant Toll-Free Dial-In Number: (833)
614-1551
US/Canada Participant International Dial-In Number: (914)
987-7290
United Kingdom International Dial-In Number: 0800 9174 860
United Kingdom Local Dial-In Number: 0203 1070 289
Conference ID:9287147
Webcast Registration link:
https://edge.media-server.com/mmc/p/saaze8yw
Auditor Change
The Audit Committee of the Company's Board of Directors approved
the dismissal of Deloitte & Touche LLP effective May 12, 2021.
Ernst & Young LLP has been appointed as the Company's successor
auditor for U.S. reporting, effective May 12, 2021, and for the
fiscal year ended June 30, 2021. PKF Littlejohn LLP remains the
Company's U.K. statutory auditors.
There were no disagreements with Deloitte on any matter of
accounting principles or practices, financial statement disclosure
or auditing scope or procedures.
For further information, please contact:
UK Investor Contact:
Walbrook PR Limited Tel: 020 7933 8780 or renalytix@walbrookpr.com
Paul McManus / Lianne Cawthorne Mob: 07980 541 893 / 07584 391
303
US Investor Contact:
Gilmartin Group i nvestors@renalytix.com
Carrie Mendivil / Mary Kate McDonough 415-937-5405
About Renalytix
Renalytix is a developer of artificial intelligence-enabled
clinical in vitro diagnostic solutions for kidney disease, one of
the most common and costly chronic medical conditions globally.
Renalytix's products are being designed to make significant
improvements in kidney disease diagnosis, transplant management,
clinical care, patient stratification for drug clinical trials, and
drug target discovery. For more information, visit
www.renalytix.com .
Forward Looking Statements
This press release contains forward-looking statements that are
based on management's beliefs and assumptions and on information
currently available to management. All statements contained in this
release other than statements of historical fact are
forward-looking statements, including statements regarding our
ability to develop, commercialize and achieve market acceptance of
our current and planned products and services, our research and
development efforts, and other matters regarding our business
strategies, use of capital, results of operations and financial
position, and plans and objectives for future operations.
In some cases, you can identify forward-looking statements by
the words "may," "will," "could," "would," "should, " "expect,"
"intend," "plan," "anticipate," "believe," "estimate," "predict,"
"project," "potential," "continue, " "ongoing" or the negative of
these terms or other comparable terminology, although not all
forward-looking statements contain these words. These statements
involve risks, uncertainties and other factors that may cause
actual results, levels of activity, performance, or achievements to
be materially different from the information expressed or implied
by these forward-looking statements. These risks, uncertainties and
other factors are described under "Risk Factors," "Management's
Discussion and Analysis of Financial Condition and Results of
Operations" and elsewhere in the documents we file with the
Securities and Exchange Commission from time to time. We caution
you that forward-looking statements are based on a combination of
facts and factors currently known by us and our projections of the
future, about which we cannot be certain. As a result, the
forward-looking statements may not prove to be accurate. The
forward-looking statements in this press release represent our
views as of the date hereof. We undertake no obligation to update
any forward-looking statements for any reason, except as required
by law.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
NORSSEESUEFSESM
(END) Dow Jones Newswires
June 10, 2021 02:00 ET (06:00 GMT)
Renalytix (LSE:RENX)
Historical Stock Chart
From Apr 2024 to May 2024
Renalytix (LSE:RENX)
Historical Stock Chart
From May 2023 to May 2024